Cell-free DNA in large B-cell lymphoma: MRD and beyond.

Brian J Sworder, David M Kurtz

Open access · greenAbstract read

In one paragraph

Article in Seminars in hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.8field-weighted citation impact, top 27% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Brian J SworderDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA.

David M KurtzDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA; Stanford Cancer Institute, Stanford University, Stanford, CA. Electronic address: dkurtz@stanford.edu.

Stanford Medicine · USStanford University · US

Funding

Molecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNAK08CA241076 · NCI · STANFORD UNIVERSITY · PI KURTZ, DAVID MATTHEW · 2019 to 2023

$957k

NCI NIH HHS K08 CA241076

6 · The paper itself

Abstract

Large B-cell lymphomas (LBCLs) are a strikingly diverse set of diseases, including clinical, biological, and molecular heterogeneity. Despite a wealth of information resolving this heterogeneity in the research setting, applying molecular features routinely in the clinic remains challenging. The advent of circulating tumor DNA (ctDNA) liquid biopsies promises to unlock additional molecular information in the clinic, including mutational genotyping, molecular classification, and minimal residual disease detection. Here, we examine the technologies, applications, and studies exploring the utility of ctDNA in LBCLs.

Indexed as

Cell-Free Nucleic AcidsCirculating Tumor DNALymphoma, B-CellBiomarkers, TumorHumansNeoplasm, ResidualBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNACell-free DNACirculating tumor DNALiquid biopsyLymphomaMinimal residual disease

Identifiers

PMID37474409

DOI10.1053/j.seminhematol.2023.06.004

PMCPMC10528139

OpenAlexW4383498261

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.